Anti-Müllerian Hormone (AMH)
AMH is a glycoprotein produced by granulosa cells of small antral ovarian follicles. Its serum level reflects how many small follicles are currently active in the ovaries.1 That is a snapshot of this cycle's follicular activity, not a fixed inventory or a permanent verdict on reproductive potential.
What AMH does not measure is equally important. It does not measure egg quality, follicle quality, or how well ovulation is functioning. For natural conception, one competent follicle per cycle is the target. A single well-developed, well-supported follicle is sufficient. A systematic review and meta-analysis found that serum AMH has poor predictive value for spontaneous pregnancy, and a low AMH level is not, on its own, associated with reduced natural fertility.2
AMH's significance as a "low" number is largely anchored to protocols requiring multiple egg retrieval. That is the IVF context. An RRM clinician asks a different question: what is this cycle's follicle doing? The total pool size is a starting point for the workup, not the answer. A 2018 cohort of 403 women with an average of 2.1 prior IVF attempts achieved a live birth rate of 32.1% through restorative care, a result that challenges any prognosis built on egg-retrieval numbers alone.3
A low AMH result is a diagnostic signal. The question is why. Age is one factor. But autoimmune conditions, prior ovarian surgery, endometriosis, vitamin D deficiency, and thyroid dysfunction can all reduce AMH before age alone explains it.4 AMH can change. A meta-analysis found DHEA supplementation significantly raised serum AMH in women with diminished ovarian reserve.5 Treating correctable contributors is the first step.
AMH also has a ceiling problem. In PCOS, AMH is often markedly elevated because many small follicles accumulate without maturing.6 A high number is not simply reassuring. It reflects arrested follicle development that warrants investigation.
In RRM practice, AMH is interpreted alongside AFC, cycle chart patterns, timed hormonal panels, and a follicle maturation study when indicated. AMH also has a developmental role: it is produced by Sertoli cells in males during fetal development and drives regression of the Müllerian ducts.1 This dual origin is why AMH appears in male factor evaluation as a marker of Sertoli cell function. The number alone is not the diagnosis. It is the beginning of the workup.
Cited in this entry
- Dewailly D, Andersen CY, Balen A, Broekmans F, Dilaver N, Fanchin R, et al. The physiology and clinical utility of anti-Müllerian hormone in women. Human Reproduction Update. 2014. https://pubmed.ncbi.nlm.nih.gov/24430863/
- Lin C, Jing M, Zhu W, Tu X, Chen Q, Wang X, et al. The value of anti-Müllerian hormone in the prediction of spontaneous pregnancy: a systematic review and meta-analysis. Frontiers in Endocrinology. 2021. https://pubmed.ncbi.nlm.nih.gov/34721287/
- Boyle PC, de Groot T, Andralojc KM, Parnell TA. Healthy singleton pregnancies from restorative reproductive medicine (RRM) after failed IVF. Frontiers in Medicine. 2018. https://pubmed.ncbi.nlm.nih.gov/30109231/
- Younis JS, Shapso N, Ben-Sira Y, Nelson SM, Izhaki I. Endometrioma surgery: a systematic review and meta-analysis of the effect on antral follicle count and anti-Müllerian hormone. American Journal of Obstetrics and Gynecology. 2022. https://pubmed.ncbi.nlm.nih.gov/34265271/
- Yin WW, Huang CC, Chen YR, Yu DQ, Jin M, Feng C. The effect of medication on serum anti-müllerian hormone (AMH) levels in women of reproductive age: a meta-analysis. BMC Endocrine Disorders. 2022. https://pubmed.ncbi.nlm.nih.gov/35698127/
- Teede H, Misso M, Tassone EC, Dewailly D, Ng EH, Azziz R, et al. Anti-Müllerian hormone in PCOS: a review informing international guidelines. Trends in Endocrinology and Metabolism. 2019. https://pubmed.ncbi.nlm.nih.gov/31160167/
Authoritative References
How other clinical authorities define this term. RRM Academy curates these verbatim or under fair use so the medical consensus is visible alongside our RRM-contextualized definition above.
- PubMed MeSH D054304
A glycoprotein that causes regression of MULLERIAN DUCTS. It is produced by SERTOLI CELLS of the TESTES. In the absence of this hormone, the Mullerian ducts develop into structures of the female reproductive tract. In males, defects of this hormone result in persistent Mullerian duct, a form of MALE PSEUDOHERMAPHRODITISM. Year introduced: 2008 (1975)
- NCI Thesaurus (Anti-Müllerian Hormone Measurement) C120625
A measurement of the anti-Mullerian hormone in a biological specimen.
- MedlinePlus (National Library of Medicine)
An anti-müllerian hormone (AMH) test measures the amount of AMH in a blood sample. In healthy females of childbearing age, higher levels of AMH mean that the ovaries have a larger supply of eggs. An AMH test can tell you the size of your ovarian reserve, but it can't tell you about the health of your eggs or predict whether you'll be able to get pregnant.
- Wikipedia
Anti-Müllerian hormone (AMH), also known as Müllerian-inhibiting factor (MIF), is a protein that in humans is encoded by the AMH gene.
This content is for educational purposes only and does not constitute medical advice. Consult an RRM clinician or healthcare provider for guidance specific to your situation.